Impact of CYP3A5 genotype on tacrolimus management in adult heart transplant recipients

被引：0
|
作者：
Pasternak, Amy [1 ]
Hong, Je-Won [1 ]
Lewis, Sarah [1 ]
机构：
[1] Univ Michigan, Coll Pharm, Ann Arbor, MI USA
来源：
PHARMACOGENETICS AND GENOMICS | 2025年 / 35卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：35 / 36
页数：2
相关论文
共 50 条
  • [1] Impact of Donor and Recipient CYP3A5*3 Genotype on Tacrolimus Population Pharmacokinetics in Chinese Adult Liver Transplant Recipients
    Shao, Jia
    Wang, Chenyu
    Fu, Peng
    Chen, Fan
    Zhang, Yi
    Wei, Jinxia
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (07) : 652 - 661
  • [2] CYP3A5 Genotype Had no Impact on Intrapatient Variability of Tacrolimus Clearance in Renal Transplant Recipients
    Spierings, N.
    Holt, D. W.
    MacPhee, Iain A. M.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (03) : 328 - 331
  • [3] Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Cardiac Transplant Recipients
    Wu, Yanting
    Eadon, Michael T.
    Schenkelberg, Laurie
    Rao, Roopa A.
    Skaar, Todd C.
    Tillman, Emma M.
    Shugg, Tyler A.
    PHARMACOGENETICS AND GENOMICS, 2025, 35 (01): : 20 - 20
  • [4] Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients
    Gijsen, Violette
    Mital, Seema
    van Schaik, Ron H.
    Soldin, Offie P.
    Soldin, Steven J.
    van der Heiden, Ilse P.
    Nulman, Irena
    Koren, Gideon
    de Wildt, Saskia N.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (12): : 1352 - 1359
  • [5] Clinical impact of reassessed tacrolimus starting dose according to CYP3A5 genotype in kidney transplant recipients
    Largeau, B.
    Barin-Le Guellec, C.
    Longuet, H.
    Lesne, P.
    Bouvarel, A.
    Preteseille, L.
    Halimi, J. M.
    Buchler, M.
    Gatault, P.
    Noble, J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 38 - 38
  • [6] Influence of the Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients
    Ferraresso, Mariano
    Tirelli, Amedea
    Ghio, Luciana
    Grillo, Paolo
    Martina, Valentina
    Torresani, Erminio
    Edefonti, Alberto
    PEDIATRIC TRANSPLANTATION, 2007, 11 (03) : 296 - 300
  • [7] CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
    Renders, L.
    Frisman, M.
    Ufer, M.
    Mosyagin, I.
    Haenisch, S.
    Ott, U.
    Caliebe, A.
    Dechant, M.
    Braun, F.
    Kunzendorf, U.
    Cascorbi, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) : 228 - 234
  • [8] Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients
    Zhang, H. J.
    Li, D. Y.
    Zhu, H. J.
    Fang, Y.
    Liu, T. S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (04) : 425 - 432
  • [9] Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus
    Pasternak, Amy L.
    Marshall, Vincent D.
    Gersch, Christina L.
    Rae, James M.
    Englesbe, Michael
    Park, Jeong M.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 319 - 326
  • [10] Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant Patients: Impact of CYP3A5 Genotype on Starting Dose
    Bergmann, Troels K.
    Hennig, Stefanie
    Barraclough, Katherine A.
    Isbel, Nicole M.
    Staatz, Christine E.
    THERAPEUTIC DRUG MONITORING, 2014, 36 (01) : 62 - 70
12345